In one of my previous roles in business I was the supply chain...

In one of my previous roles in business I was the supply chain representative on the product development review group. Our company was not as large as CSL, but I would suggest that the processes and rigour that CSL employ would be the same or better than what I experienced. When I was on the group the aim was to find reasons to stop the spending on R & D. By that comment, I mean that there was a huge amount of questioning and rigour around letting ideas proceed along the path to market.
CSL112 would, I am assuming be subject to the same processes as any other drug in development.
This understanding of the processes gives me some confidence that they would not be spending more than $1B on phase 3 trials if they did not have confidence that the chance of success was more than 50%.

HT1